

# Support from the Start



## in Rheumatoid Arthritis

In the majority of RA patients erosions occurred within 2 years of onset of joint symptoms.<sup>1</sup>

Fortunately, earlier introduction of disease-modifying agents in RA is a growing trend.<sup>2</sup>

When non-steroidal therapy fails, even early in the disease process, Salazopyrin EN-tabs

demonstrate rapid symptomatic improvement<sup>3</sup> and slowing of radiographic progression of joint damage.<sup>4</sup>


"... the best prospect for successful treatment with [Salazopyrin EN-tabs] ... is early in the course of RA."<sup>5</sup>

GO FOR EARLIER INTERVENTION

# Salazopyrin<sup>®</sup>

## EN-tabs

(enteric-coated sulphasalazine)



## YOUR FIRST STEP TO SUPPRESS JOINT EROSION

### Abbreviated Prescribing Information

**Presentation:** Yellow enteric coated tablets, logo on one side, containing sulphasalazine 0.5g. **Uses:** Rheumatoid Arthritis unresponsive to NSAIDs. **Dose:** Do not break tablets. *Adults/Elderly:* 0.5g/day for a week, dose increasing by 0.5g/day weekly to a maximum of 3g/day in divided doses. *Children:* no recommendation. **Contra-indications:** Sulphonamide or salicylate sensitivity. **Infants under 2 years of age.** **Precautions:** Monthly blood checks and LFTs for 3 months. Care in hepatic, renal disease, porphyria or glucose-6-phosphate dehydrogenase deficiency. **Adverse Effects:** Nausea, headache, rash, loss of appetite, raised temperature. Rarely serious ADRs; *Haematological:* e.g. marrow depression, anaemias; *Hypersensitivity:* e.g. Stevens-Johnson syndrome, photosensitivity, lung complications, fever; *G-I Reactions:* e.g. hepatitis; *CNS:* e.g. neuropathy; *Fertility:* reversible oligospermia; *Renal:* e.g. proteinuria. **Pregnancy and Lactation:** No evidence for teratogenic or icteric hazards. Drug in breast milk should not be a risk to healthy infant. **Package Quantities:** 125 tablets in easy-open pack. **Basic NHS Cost:** EN-tabs 125 (UK price) £12.75. **Legal Status:** POM (Prescription Only Medicine). **UK Product Licence Number:** PL 0009/5007R. **Product Authorisation Number (Ireland):** PA107/5/2. **Product Licence and Product Authorisation Holder:** Pharmacia Biotech Ltd, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. **Distributed in UK by:** Kabi Pharmacia Ltd, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH. **Tel:** (0908) 661101. **Distributed in Ireland by:** Cahill May Roberts for Kabi Pharmacia (Ireland) Ltd, Chapelizod, Dublin 20. **References:** 1. Brook A, Corbett M. *Annals of the Rheumatic Diseases* 1977; 36: 71-73. 2. Spector TD, et al. *British Journal of Rheumatology* 1988; 27: 498-9. 3. Reilly PA, Burns A, Moran CJ. Letter to: *Clinical and Experimental Rheumatology* 1991; 9 (1): 90-91. 4. van der Heijde DM, et al. *Lancet* 1990; i: 539. 5. Situnayake RD, McConkey B. *The Journal of Rheumatology* 1990; 17: 1268-73.



Kabi Pharmacia